Cholesterol News and Research RSS Feed - Cholesterol News and Research

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid. Cholesterol also comes from eating foods taken from animals such as egg yolks, meat, and whole-milk dairy products. Too much cholesterol in the blood may build up in blood vessel walls, block blood flow to tissues and organs, and increase the risk of developing heart disease and stroke.
Researchers uncover intriguing link between heart attacks and protein

Researchers uncover intriguing link between heart attacks and protein

A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol. [More]
Novel polypill increases patient adherence to treatment following heart attack

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain. [More]
Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014. [More]
New polypill increases adherence to treatment following myocardial infarction

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US. [More]
'Good' cholesterol turns 'bad' by sugar-derived substance

'Good' cholesterol turns 'bad' by sugar-derived substance

Scientists at the University of Warwick have discovered that 'good' cholesterol is turned 'bad' by a sugar-derived substance. [More]
BIOCRATES launches first-ever bile acids kit based on targeted metabolite quantitation

BIOCRATES launches first-ever bile acids kit based on targeted metabolite quantitation

Austrian BIOCRATES Life Sciences AG, internationally renowned developer and marketer of innovative targeted metabolomics solutions, further expands its range of metabolomics-based kits with the addition of its assay for the determination of endogenous bile acids, allowing a panel of up to 19 analytes to be simultaneously quantitated from a single 10 ┬ÁL sample of human or mouse plasma. [More]
Combination of moderate wine drinking plus regular exercise protects against CVD

Combination of moderate wine drinking plus regular exercise protects against CVD

Wine only protects against cardiovascular disease (CVD) in people who exercise, according to results from the In Vino Veritas (IVV) study presented at ESC Congress today by Professor Milos Taborsky from the Czech Republic. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]
Risk-based treatment approach should be considered for patients with hypertension

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis. [More]
Merz Pharmaceuticals launches new CAIDE Dementia Risk App

Merz Pharmaceuticals launches new CAIDE Dementia Risk App

The CAIDE Dementia Risk App from Merz Pharmaceuticals is available free of charge for people from 40 to 65 to calculate their individual risk for getting dementia within the next two decades. Using a traffic light color scheme, the App can also help physicians discuss preventive measures with patients at risk. [More]
Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. [More]
New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs. [More]
Receiving prescription at discharge improves outcomes in stroke patients

Receiving prescription at discharge improves outcomes in stroke patients

Stroke patients are 70 per cent more likely to continue taking their stroke prevention medications one year later if they have a prescription in hand when discharged - according to researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences. [More]
Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen's ivabradine receives FDA priority review designation for treatment of chronic heart failure

Amgen today announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). [More]
New guidelines can improve the way statin drugs prescribed to patients at cardiovascular risk

New guidelines can improve the way statin drugs prescribed to patients at cardiovascular risk

New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease, a Yale University study has found. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Spanish scientists explore genetic basis of familial extreme longevity

Spanish scientists explore genetic basis of familial extreme longevity

In a recent report in Aging Cell, a multidisciplinary team of Spanish scientists, led by Tim Cash and Manuel Serrano at the Spanish National Cancer Research Centre, identify rare variants in the APOB gene in several families where exceptional longevity (>100 years of age) appears to cluster. [More]

New ingredient in gluten-free products can cause allergic reaction

A popular new ingredient in gluten-free products could be causing an allergic reaction, according to a Kansas State University food safety specialist. [More]
UT Southwestern researchers discover crucial link between high insulin levels and obesity pathways

UT Southwestern researchers discover crucial link between high insulin levels and obesity pathways

UT Southwestern Medical Center researchers have identified a crucial link between high levels of insulin and pathways that lead to obesity, a finding that may have important implications when treating diabetes. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]